T1	Participants 71 138	patients having coronary stent implantation treated with prasugrel.
T2	Participants 211 295	patients with acute coronary syndromes undergoing percutaneous coronary intervention
T3	Participants 496 618	298 consecutive patients 68 Â± 10 years old (31% >75 years old) underwent stent implantation and received prasugrel therapy
T4	Participants 620 983	Indications to prasugrel therapy were (1) ST-elevation acute myocardial infarction (41%), (2) drug-eluting stent implantation in diabetics (24%), (3) stent thrombosis (3%), (4) left main coronary artery drug-eluting stent implantation (6%), and (5) percutaneous coronary intervention in patients with high residual platelet reactivity on clopidogrel therapy (26%)
